Eli Lilly UNITED STATES And PUERTO RICO — Non-Current Assets increased by 40.0% to $18.76B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 40.0%, from $13.40B to $18.76B.
An increase suggests significant capital investment or expansion of manufacturing and research facilities in the region, while a decrease may indicate asset divestitures, depreciation, or a shift in capital allocation strategy.
This metric represents the total value of long-term assets, such as property, plant, equipment, and intangible assets, a...
Comparable to regional non-current asset disclosures in other multinational pharmaceutical companies, reflecting the geographic distribution of production and R&D infrastructure.
lly_segment_unitedstates_and_puertorico_noncurrent_assets| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $6.62B | $7.71B | $9.99B | $13.40B | $18.76B |
| QoQ Change | — | +16.5% | +29.6% | +34.1% | +40.0% |
| YoY Change | — | +16.5% | +29.6% | +34.1% | +40.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.